Role of Tranexamic acid in reducing blood loss during Cesarean section.

Evaluating the Efficacy and Timing of Tranexamic Acid Administration in Reducing Bleeding During and After Elective Lower Segment Cesarean Sections: A Randomized Double-Blind Placebo-Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067500

Enrollment

260

Registered

2024-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Intravenous Tranexamic acid 1g: Group I: Intravenous Tranexamic acid 1g at the time of skin incision. Group II: Intravenous Tranexamic acid 1g at the time of cord clamping for a duratio

Eligibility

Inclusion criteria

Inclusion criteria: All antenatal women = 18 years of age with singleton pregnancy planned for elective LSCS at gestation = 34 weeks.

Exclusion criteria

Exclusion criteria: 1. Women undergoing vaginal delivery 2. History of coagulation or thrombotic disorders, 3. Emergency LSCS, 4. Abruption or placenta praevia, 5. Abnormally invasive placenta, 6. Multifetal gestation, 7. Preeclampsia or HELLP syndrome, 8. Eclampsia, 9. Intrauterine fetal demise, 10. Polyhydramnios, 11. History of epilepsy or seizure, 12. Anticoagulant drugs or LMW Heparin, 13. Anemia/cardiac/renal/liver disease, 14. Hypersensitivity to TXA, 15. CS being done under General anesthesia.

Design outcomes

Primary

Measure	Time frame
The current research aims to assess the effectiveness, timing, and safety of TXA in reducing blood loss in women undergoing elective LSCS. If the study confirms the positive impact of TXA in reducing blood loss during LSCS, it can serve as the basis for developing institutional guidelines regarding the optimal timing of TXA administration as a prophylactic measure to prevent PPH, potentially saving numerous maternal lives from this complication.Timepoint: The assessment will be done during intra-operative period and within first 24 hours of cesarean section.	—

Measure

Time frame

The current research aims to assess the effectiveness, timing, and safety of TXA in reducing blood loss in women undergoing elective LSCS. If the study confirms the positive impact of TXA in reducing blood loss during LSCS, it can serve as the basis for developing institutional guidelines regarding the optimal timing of TXA administration as a prophylactic measure to prevent PPH, potentially saving numerous maternal lives from this complication.Timepoint: The assessment will be done during intra-operative period and within first 24 hours of cesarean section.

—

Secondary

Measure	Time frame
To assess the potential adverse effects of Tranexamic acid (1 g) during & after cesarean sectionTimepoint: Intraoperative & immediate post-operative period (within 24 hours of cesarean section)	—

Countries

India

Contacts

Public ContactNaina Kumar

AIIMS, Bibinagar

drnainakumar@gmail.com9552515600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026